The Valley Desk

NCT02935686 · Interventional trial

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

Overall registry status Completed

Phase 1 · Phase 2

Conditions Healthy

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov